On April 21-22 2022, BIOCELLPHE Consortium met for the first time live with all team members to discuss the project updates and plan the next steps to advance in the development of a breakthrough technology realizing the identification of proteins (i.e. phenotyping) as diagnostic biomarkers at single-cell level with unmatched sensitivity, multiplexing capabilities and portability.
BIOCELLPHE project proposes the generation of engineered bacteria able to recognize and bind to specific protein targets on the surface of circulating tumor cells (CTCs) responsible for cancer metastasis, thereby triggering the production of chemical signals that can be detected simultaneously, and with extremely high sensitivity by surface-enhanced Raman scattering (SERS).
SERS is a powerful analytical technique that employs plasmonic nanoparticles as optical enhancers for ultrasensitive chemical analysis achieving single-molecule detection level.
BIOCELLPHE has the potential to usher in a new era of medical diagnostics and it will provide new paradigms in biology and biomedicine, advancing frontier science and technologies at the European academic and industrial sectors.